Sun Pharma has formed a distribution partnership with Mitsubishi Tanabe Pharma Corporation in Japan for the 14 prescription brands acquired from Novartis.
The move marks the initiation of a phased transfer of manufacturing and marketing rights of the products in Japan, which were acquired for $293m.
The prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma to Sun Pharma’s subsidiary in Japan, beginning October this year.
The brands are Parlodel, Lamisil, Nitroderm, Apresoline, Zaditen, Symmetrel, Cibacen, Tegretol, Pursennid, Lioresal, Lopresor, Ternelin, Ludiomil and Lochol.
The transfer of these brands will be completed by the end of next year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFollowing the transfer, Mitsubishi Tanabe Pharma will market and distribute all the 14 brands, as well as provide information on their proper use to healthcare professionals.
Sun Pharma Japan president and representative director Isao Muramatsu said: “Through this alliance we have the opportunity to leverage Mitsubishi Tanabe Pharma Corporation’s specialised expertise to create a strong business foundation for us in Japan.
“Sun Pharma will focus on expanding its sales channels in Japan’s pharmaceutical market while continuing to ensure a stable supply of medicines and healthcare information.”
Sun Pharma currently operates 47 manufacturing facilities across six continents and R&D centres worldwide.
The company’s R&D capabilities are supported by more than 2,000 scientists.
